The evolution of acute myeloid leukaemia by in situ transformation of haematopoietic stem cells

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1098470

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Acute myeloid leukaemia (AML) is a devastating form of blood cancer that can affect people of any age. The survival of patients with AML is poor and this is because the disease usually comes back after chemotherapy (this is called relapse). Fewer than half of all patients with AML can be cured. We have recently developed a new, and improved, model of AML in the lab, which we will use to test an exciting new treatment for patients with AML.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $646,966.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Haematology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

acute myeloid leukaemia (AML) | cancer biology | leukaemia | stem cell biology | targeted therapy

Related Links